Expertise in
17
conditions

Dr. Morris Groves

Neurology
Texas Oncology Pharmacy-Austin Mid
901 W 38th St Ste 200, 
Austin, TX 
Expertise in
17
conditions
Texas Oncology Pharmacy-Austin Mid
901 W 38th St Ste 200, 
Austin, TX 

Overview

Morris Groves is a Neurologist practicing medicine in Austin, Texas.

Dr. Groves is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Glioblastoma, and Astrocytoma.

He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 6 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO

Locations

Texas Oncology Pharmacy-Austin Mid
901 W 38th St Ste 200, Austin, TX 78705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative
Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative
Enrollment Status: Terminated
Publish Date: November 19, 2024
Intervention Type: Other, Radiation, Procedure, Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

33 Total Publications

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: July 21, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Elliot Frohman
Neurology
Expertise in
8
conditions
Dr. Elliot Frohman
Neurology
Referral may be required

The Univ. Of Texas At Austin

1601 Trinity St, 
Austin, TX 
 (1.9 miles away)
512-495-5000
Languages Spoken:
English
See accepted insurances

Elliot Frohman is a Neurologist practicing medicine in Austin, Texas. Dr. Frohman is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Optic Neuritis, Relapsing Multiple Sclerosis (RMS), and Transverse Myelitis.

Expertise in
7
conditions
Dr. Edward Fox
Neurology
Expertise in
7
conditions
Dr. Edward Fox
Neurology
Referral may be required

Ascension Seton Medical Center Austin

1201 W 38th St, 
Austin, TX 
 (0.2 miles away)
512-218-1222
Languages Spoken:
English
See accepted insurances

Edward Fox is a Neurologist practicing medicine in Austin, Texas. Dr. Fox is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Relapsing Multiple Sclerosis (RMS), Multiple Sclerosis (MS), Neuromyelitis Optica, Osteotomy, and Vertebroplasty.

Expertise in
17
conditions
Dr. Michael Soileau
Neurology
Expertise in
17
conditions
Dr. Michael Soileau
Neurology
Referral may be required

Texas Movement Disorder Specialists PLLC

204 S Interstate 35 Ste 103, 
Georgetown, TX 
 (24.9 miles away)
512-693-4041
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Soileau is a Neurologist practicing medicine in Georgetown, Texas. Dr. Soileau is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Essential Tremor, Deep Brain Stimulation, and Gastrostomy.

Frequently Asked Questions about Dr. Morris Groves

How do I make an appointment with Dr. Morris Groves?

You can book an appointment with Dr. Morris Groves by calling their office at 512-421-4100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Morris Groves a top-rated expert for Brain Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Morris Groves is classified as an Distinguished expert for Brain Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Morris Groves specialize in?

While Dr. Morris Groves is a Neurology, they have specific expertise in Brain Tumor, Glioma, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Morris Groves participate in research or clinical trials?

Yes. Dr. Morris Groves has published 33 articles and abstracts on conditions like Brain Tumor. You can view a list of Dr. Morris Groves's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Morris Groves accept my insurance?

Dr. Morris Groves accepts most major insurance plans, including Medicare and Oscar. We recommend calling the office directly at 512-421-4100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Groves's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile